Cystatin C has received increasing attention as a potential biomarker for cognitive impairment in the older population because studies found that cystatin C colocalizes with β-amyloid in the brains of individuals with Alzheimer’s disease (AD; Levy et al., 2001; Sastre et al., 2004). This evidence concerns the gene CST3 and Alzheimer disease.